These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 20737510)

  • 1. Anti-JC virus antibodies: implications for PML risk stratification.
    Gorelik L; Lerner M; Bixler S; Crossman M; Schlain B; Simon K; Pace A; Cheung A; Chen LL; Berman M; Zein F; Wilson E; Yednock T; Sandrock A; Goelz SE; Subramanyam M
    Ann Neurol; 2010 Sep; 68(3):295-303. PubMed ID: 20737510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
    Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
    J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
    Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
    Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma.
    Plavina T; Berman M; Njenga M; Crossman M; Lerner M; Gorelik L; Simon K; Schlain B; Subramanyam M
    J Clin Virol; 2012 Jan; 53(1):65-71. PubMed ID: 22104399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
    Rudick RA; O'Connor PW; Polman CH; Goodman AD; Ray SS; Griffith NM; Jurgensen SA; Gorelik L; Forrestal F; Sandrock AW; Goelz SE
    Ann Neurol; 2010 Sep; 68(3):304-10. PubMed ID: 20737514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Plavina T; Subramanyam M; Bloomgren G; Richman S; Pace A; Lee S; Schlain B; Campagnolo D; Belachew S; Ticho B
    Ann Neurol; 2014 Dec; 76(6):802-12. PubMed ID: 25273271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
    Dominguez-Mozo MI; Rus M; Santiago JL; Izquierdo G; Casanova I; Galan V; Garcia-Martinez MA; Arias-Leal AM; García-Montojo M; Pérez-Pérez S; Arroyo R; Alvarez-Lafuente R
    Eur J Clin Invest; 2017 Feb; 47(2):158-166. PubMed ID: 28036121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
    Carruthers RL; Chitnis T; Healy BC
    Mult Scler; 2014 May; 20(6):757-60. PubMed ID: 24189572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy.
    Du Pasquier RA; Kuroda MJ; Zheng Y; Jean-Jacques J; Letvin NL; Koralnik IJ
    Brain; 2004 Sep; 127(Pt 9):1970-8. PubMed ID: 15215217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.
    Bozic C; Richman S; Plavina T; Natarajan A; Scanlon JV; Subramanyam M; Sandrock A; Bloomgren G
    Ann Neurol; 2011 Nov; 70(5):742-50. PubMed ID: 22162056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial.
    Bozic C; Subramanyam M; Richman S; Plavina T; Zhang A; Ticho B
    Eur J Neurol; 2014 Feb; 21(2):299-304. PubMed ID: 24894998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
    Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An assay to quantify species-specific anti-JC virus antibody levels in MS patients.
    Warnke C; Pawlita M; Dehmel T; Posevitz-Fejfar A; Hartung HP; Wiendl H; Kieseier BC; Adams O
    Mult Scler; 2013 Aug; 19(9):1137-44. PubMed ID: 23388163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification.
    Laroni A; Giacomazzi CG; Grimaldi L; Gallo P; Sormani MP; Bertolotto A; McDermott JL; Gandoglia I; Martini I; Vitello G; Rinaldi F; Barzon L; Militello V; Pizzorno M; Bandini F; Capello E; Palù G; Uccelli A; Mancardi GL; Varnier OE
    J Neuroimmune Pharmacol; 2012 Sep; 7(3):665-72. PubMed ID: 22585413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes to anti-JCV antibody levels in a Swedish national MS cohort.
    Warnke C; Ramanujam R; Plavina T; Bergström T; Goelz S; Subramanyam M; Kockum I; Rahbar A; Kieseier BC; Holmén C; Olsson T; Hillert J; Fogdell-Hahn A
    J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1199-205. PubMed ID: 23463870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
    Sørensen PS; Bertolotto A; Edan G; Giovannoni G; Gold R; Havrdova E; Kappos L; Kieseier BC; Montalban X; Olsson T
    Mult Scler; 2012 Feb; 18(2):143-52. PubMed ID: 22312009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
    Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
    Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab.
    Ryschkewitsch CF; Jensen PN; Monaco MC; Major EO
    Ann Neurol; 2010 Sep; 68(3):384-91. PubMed ID: 20818792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.